Biote Corp. rose 2.82% intraday, with RTW Biotech Opportunities Ltd signing a $75 million financing deal, and RTW Biotech joining Aquestive Therapeutics' funding to support oral drug development. RTW Biotech is focused on high-growth life science assets, and Aquestive Therapeutics is developing Anaphylm, an orally delivered film for the emergency treatment of type 1 allergic reactions.
Comments
No comments yet